2024-06-07 11:15:07 ET
Summary
- Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss.
- Viking stock has become more volatile due to competition from other biotechs sharing compelling weight loss data themselves, and the supremacy of Eli Lilly / Novo Nordisk in the field.
- Viking's latest data on its other lead drug candidate VK2809 for NASH, released this week, did not impress the market, leading to a decline in stock price.
- Viking has two good drugs in development, but needs to show that one or the other is approvable, with "best-in-class" potential.
- As competition hots up in weight loss and NASH markets, the company faces an uncertain outlook - more and better data may be needed to keep the stock price buoyant.
Investment Thesis - Viking Stock Spikes >200% On Obesity Data, Sinks On MASH Data
Read the full article on Seeking Alpha
For further details see:
Viking Therapeutics: MASH Data Punished By Wall Street Amid GLP-1 Uncertainty